Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis

2019; Elsevier BV; Volume: 7; Issue: 3 Linguagem: Inglês

10.1016/s2214-109x(18)30491-1

ISSN

2572-116X

Autores

Micah Silaba Ominde, Michael Ooko, Christian Bottomley, Joyce Sande, Rachel Benamore, Kate Park, James Ignas, Kathryn Maitland, Neema Mturi, Anne Makumi, Mark Otiende, Stanley Kagwanja, Sylvester Safari, Victor Ochola, Tahreni Bwanaali, Evasius Bauni, Fergus Gleeson, Maria Deloria Knoll, Ifedayo Adetifa, Kevin Marsh, Thomas N. Williams, Tatu Kamau, Shahnaaz Sharif, Orin S. Levine, Laura L. Hammitt, J. Anthony G. Scott,

Tópico(s)

Respiratory viral infections research

Resumo

Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal disease caused by vaccine serotypes, but the burden of pneumococcal disease in low-income and middle-income countries is dominated by pneumonia, most of which is non-bacteraemic. We examined the effect of 10-valent PCV on the incidence of pneumonia in Kenya.

Referência(s)